Glucose monitoring has been important for diabetic patients. The automated bedside monitoring device for ICU by OptiScan Medical, California-based company, earned a CE mark. The device continuously monitors blood glucose and lactate.
Let’s take a look at the functioning of this device.
The OptiScanner 6000, a successor of OptiScanner 5000, is a bedside glucose tracking device for the critically ill patients. The system extracts blood, 0.13 ml every 15 minutes, and then separates the plasma to be examined through an infrared spectrometer. The blood glucose results are displayed on the screen of the device. Along with blood glucose readings, the device also monitors lactate levels simultaneously from the same blood sample.
Thus, the OptiScanner can help the physicians to improve outcomes of the critically ill patients by enabling continuous monitoring and hence controlling the adverse outcomes related to glucose and lactate levels. The device also cuts down the possibility of errors from manually extracted blood samples.
Peter Rule, CEO of OptiScan, said, “As continuous tracking of glucose is viral in the ICU, there are additional metabolites whose monitoring is equally important to improve patient care. By offering ICU physicians with the OptiScanner 6000, which can monitor glucose and lactose simultaneously from the same blood sample of the patients’ blood, we believe this device will play a crucial role in the level of care given to ICU patients.”
What do you think about the OptiScanner 6000? Isn’t this device making very helpful for the physicians and patients too? Feel free to share your thoughts.